治疗前淋巴细胞与C反应蛋白比值对结外NK/T细胞淋巴瘤预后的判断价值  

Prognostic value of pre-treatment lymphocyte-to-C-reactive protein ratio in patients with extra-nodal natural killer/T-cell lymphoma

作　　者：翟素娜[1] 张羲茜 李冰妍 赵静宜 李荣臻 杨道科[1] ZHAI Suna;ZHANG Xiqian;LI Bingyan;ZHAO Jingyi;LI Rongzhen;YANG Daoke(Department of Radiation Oncology,the First Affiliated Hospital,Zhengzhou University,Zhengzhou 450052)

机构地区：[1]郑州大学第一附属医院放疗科,郑州450052

出　　处：《郑州大学学报（医学版）》2024年第5期668-672,共5页Journal of Zhengzhou University(Medical Sciences)

基　　金：河南省医学科技攻关计划省部共建项目(SB201901037);河南省医学科技攻关计划联合共建项目(LHGJ20190046)。

摘　　要：目的:探讨治疗前淋巴细胞与C反应蛋白比值(LCR)对结外NK/T细胞淋巴瘤(ENKTL)预后的判断价值。方法:回顾性分析郑州大学第一附属医院收治的203例初诊为ENKTL患者的临床资料,ROC曲线得到LCR预测5 a总生存期(OS)的最佳截断值,并根据截断值将患者分为两组,绘制Kaplan-Meier生存曲线,采用Cox回归分析无进展生存期(PFS)和OS的影响因素。结果:LCR预测5 a OS的最佳截断值为0.19,低LCR组患者预后较差(P<0.001)。Cox回归分析结果表明,低LCR组ENKTL患者预后较差,PFS和OS的HR(95%CI)分别为0.462(0.336~0.636)和0.381(0.275~0.527)。结论:治疗前LCR可影响ENKTL预后,低LCR患者的预后较差。Aim:To investigate the value of lymphocyte-to-C-reactive protein ratio(LCR)for predicting prognosis of patients with extra-nodal natural killer/T-cell lymphoma(ENKTL)before treatment.Methods:Clinical data of 203 patients with ENKTL admitted to the First Affiliated Hospital of Zhengzhou University were retrospectively analyzed.The optimal cut-off value of LCR predicting 5 years overall survival(OS)was obtained by ROC curve,and the patients were allocated into 2 groups according to the cut-off value.The Kaplan-Meier curve was used to analyze the prognosis of patients in different LCR groups.Cox regression was used to analyze the influencing factors of progression-free survival(PFS)and OS.Results:The optimal cut-off value of LCR predicting 5 years OS was 0.19.Patients in low LCR group had poor prognosis(P<0.001).Cox regression analysis showed that low LCR group had poor prognosis,and HR(95%CI)of PFS and OS was 0.462(0.336-0.636)and 0.381(0.275-0.527).Conclusion:LCR before treatment is a new prognostic marker for ENKTL patients.Patients with low LCR may have worse prognosis.

关 键 词：淋巴细胞与C反应蛋白比值 结外NK/T细胞淋巴瘤 预后 

分 类 号：R733.1[医药卫生—肿瘤]